Richardson, Paul M.D.
Dr Paul Richardson, MD, is the RJ Corman Professor of Medicine at Harvard Medical School, Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (DFCI), Boston, USA.
Dr. Richardson has served as Principal/Co-Principal Investigator and Study Chair for several pivotal trials, including the landmark international Intergroupe Francophone du Myélome/DFCI 2009 study for newly diagnosed patients eligible for stem cell transplantation (SCT), using the combination of lenalidomide, bortezomib and dexamethasone (RVD), which has provided the basis for better understanding the role of SCT in the era of novel agents.
Dr. Richardson was also principal investigator of the phase 3 ICARIA-MM study, the results of which served as the basis for the recent FDA approval of Sarclisa (isatuximab-irfc). The trial was designed to demonstrate the benefit of isatuximab in combination with pomalidomide and low-dose dexamethasone in the prolongation of Progression Free Survival (PFS) as compared to pomalidomide and low-dose dexamethasone in patients with RRMM. In the study, Sarclisa added to pom-dex (Sarclisa combination therapy) demonstrated a statistically significant improvement in progression free survival and a significantly greater overall response rate compared to pom-dex alone.
Dr. Richardson obtained his medical degree from St Bartholomew’s Hospital Medical College, University of London, before completing residencies at Newcastle University School of Medicine, the Royal Marsden Hospital (London and Surrey) and the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. His Fellowships in hematology/oncology and medical oncology were completed at Tufts University School of Medicine, Baystate Medical Center, Springfield, USA, and at Harvard Medical School, DFCI.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.